Clinical Nuclear Medicine

Skip Navigation LinksHome > December 2013 - Volume 38 - Issue 12 > Targeted α-Particle Therapy of Bone Metastases in Prostate C...
Clinical Nuclear Medicine:
doi: 10.1097/RLU.0000000000000290
Review Article

Targeted α-Particle Therapy of Bone Metastases in Prostate Cancer

Jadvar, Hossein MD, PhD, MPH, MBA*; Quinn, David I. MD, PhD

Collapse Box


Abstract: Medical oncology is moving toward personalized and precision treatments. This evolution is spearheaded by ongoing discoveries on the fundamental machinery that controls tumor and hosts microenvironment biological behavior. α-Particles with their high energy and short range had long been recognized as potentially useful in the treatment of cancer. More than a century after the discovery of radium by the Curies, 223Ra dichloride is now available in the expanding armamentarium of therapies for metastatic castration-resistant prostate cancer. This advance occurs in the context of several other novel therapeutics in advanced prostate cancer that include more effective androgen receptor pathway inhibition, better chemotherapy, and immunotherapy. We present a concise review on the therapeutic use of 223Ra dichloride in this clinically important setting including excerpts on the radium history, physical properties, the alpharadin in symptomatic prostate cancer clinical trial, and practical information on its use in the clinic. It is anticipated that, with the current emergence of 223Ra as a viable form of therapy, interest in and use of α-particle therapy in the management of cancer will grow.

© 2013 by Lippincott Williams & Wilkins


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.